[
  {
    "page_number": 3,
    "row_name": "Antibiotic",
    "superscript_number": null,
    "ph_value": null,
    "column_name": null,
    "mark_type": null,
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "amikacin",
    "superscript_number": "1,2,3",
    "ph_value": "3.5-5.5",
    "column_name": "Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "ampicillin",
    "superscript_number": "4,5,6,7",
    "ph_value": "8.0-10.0",
    "column_name": "Phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "ampicillin and sulbactam",
    "superscript_number": "8,9",
    "ph_value": "8.0-10.0",
    "column_name": "Phlebitis.Local site pain.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "azithromycin",
    "superscript_number": "1,9",
    "ph_value": "NR*",
    "column_name": "Potential for damage from extravasation.Local site pain.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "aztreonam",
    "superscript_number": "1,10",
    "ph_value": "4.5-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "aztreonam and avibactam sodium",
    "superscript_number": "11",
    "ph_value": "4.0-8.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "capreomycin",
    "superscript_number": "12,13",
    "ph_value": "4.5-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefazolin",
    "superscript_number": "1,14",
    "ph_value": "4.0-6.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefepime",
    "superscript_number": "1,15",
    "ph_value": "5.2-5.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefiderocol sulfate tosylate",
    "superscript_number": "1,16,17",
    "ph_value": "5.0-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefotaxime sodium",
    "superscript_number": "1,18,19",
    "ph_value": "4.5-6.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefotetan disodium",
    "superscript_number": "1,20",
    "ph_value": "4.2-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefoxitin",
    "superscript_number": "1,21",
    "ph_value": "4.5-6.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain",
    "mark_type": "Circle.Circle.Circle",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "cefoperazone",
    "superscript_number": "1,22,23",
    "ph_value": "4.8-6.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain",
    "mark_type": "Circle.Circle.Circle",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "ceftaroline fosamil",
    "superscript_number": "1,24",
    "ph_value": "5.0-8.0",
    "column_name": "Phlebitis.Local site pain.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 4,
    "row_name": "ceftazidime",
    "superscript_number": "1,25",
    "ph_value": null,
    "column_name": null,
    "mark_type": null,
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 5,
    "row_name": "amikacin",
    "superscript_number": "1,2,3",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Do not physically premix with other drugs; administer separately as recommended by manufacturer. Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and vancomycin. Do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "ampicillin 4,5,6,7",
    "superscript_number": "4,5,6,7",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established. Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline. Visual signs of incompatibility are precipitation, clouding and discoloration.6",
    "superscript_in_statement": "6"
  },
  {
    "page_number": 5,
    "row_name": "ampicillin and sulbactam 8,9",
    "superscript_number": "8,9",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Frequently used concomitantly with aminoglycosides (e.g., gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer at separate sites.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "azithromycin 1,9",
    "superscript_number": "1,9",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Manufacturer states, \"Other IV substances, additives, or medications should not be added to azithromycin, or infused simultaneously through the same IV line.\" Flush IV line with a compatible IV fluid before and after administration. ¹ Local IV site reactions have been reported with the intravenous administration of azithromycin. All volunteers who received infusate concentrations above 2.0 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided. 9",
    "superscript_in_statement": "1,9"
  },
  {
    "page_number": 5,
    "row_name": "aztreonam 1,10",
    "superscript_number": "1,10",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Do not infuse simultaneously with other drugs or solutions except in proven compatibility.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "aztreonam and avibactam sodium11",
    "superscript_number": "11",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Emblaveo is administered by intravenous infusion over 3 hours. This medicinal product must not be mixed with other medicinal products except sodium chloride (0.9%) solution for injection, glucose (5%) solution for injection, or Lactated Ringer's solution as mentioned below.11",
    "superscript_in_statement": "11"
  },
  {
    "page_number": 5,
    "row_name": "capreomycin 12,13",
    "superscript_number": "12,13",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush IV line before and after administration.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "cefazolin 1,14",
    "superscript_number": "1,14",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Temporarily discontinuing other solutions infusing at the same site during intermittent infusion. May be used concomitantly with aminoglycosides (e.g., gentamicin, tobramycin), aminophylline, metronidazole, and vancomycin, but these drugs must never be mixed in the same infusion (mutual inactivation or other potential interactions). If concurrent therapy with cefepime is indicated, each of these antibiotics can be administered separately.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "cefepime 1,15",
    "superscript_number": "1,15",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "cefiderocol sulfate tosylate 1,16,17",
    "superscript_number": "1,16,17",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If Cefotan and aminoglycosides are to administered to the same patient, they must be administered separately and not as a mixed injection.20",
    "superscript_in_statement": "20"
  },
  {
    "page_number": 5,
    "row_name": "cefotaxime sodium 1,18,19",
    "superscript_number": "1,18,19",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "cefotetan disodium 1,20",
    "superscript_number": "1,20",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "cefoxitin 1,21",
    "superscript_number": "1,21",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them. 22",
    "superscript_in_statement": "22"
  },
  {
    "page_number": 5,
    "row_name": "cefoperazone 1,22,23",
    "superscript_number": "1,22,23",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Manufacturer states, Should not be mixed with or physically added to solutions containing other drugs.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "ceftaroline fosamil 1,24",
    "superscript_number": "1,24",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin, and tobramycin), but these drugs must never be mixed in the same infusion (mutual inactivation). May exhibit a physical incompatibility with vancomycin depending on concentration. If aminoglycosides or vancomycin are given concurrently, administer separately and flush IV line before and after administration. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site during intermittent infusion and states, \"Do not add supplementary medications to premixed plastic IV containers.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 5,
    "row_name": "ceftazidime 1,25",
    "superscript_number": "1,25",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 6,
    "row_name": "ceftizoxime",
    "superscript_number": "26,27",
    "ph_value": null,
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "ceftobiprole medocaril\nsodium",
    "superscript_number": "1,28,29",
    "ph_value": "4.5-5.5",
    "column_name": "Thrombosis of vessel.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "ceftolozane/tazobactam",
    "superscript_number": "1,30",
    "ph_value": "5.0-7.0",
    "column_name": "Phlebitis.Thrombosis of vessel.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "ceftriaxone",
    "superscript_number": "1,31",
    "ph_value": "6.6-6.7",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "cefuroxime",
    "superscript_number": "1,32",
    "ph_value": "5.0-8.5",
    "column_name": "Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "chloramphenicol\nsodium succinate",
    "superscript_number": "1,33",
    "ph_value": "6.4-7.0",
    "column_name": "Local site pain on Infusion.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "ciprofloxacin",
    "superscript_number": "1,34",
    "ph_value": "3.5-4.6",
    "column_name": "Thrombo-phlebitis.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "clarithromycin",
    "superscript_number": "35",
    "ph_value": null,
    "column_name": "Phlebitis.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "clindamycin",
    "superscript_number": "1,36",
    "ph_value": "5.5-7.0",
    "column_name": "Thrombo-phlebitis.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "daptomycin",
    "superscript_number": "1,37,38",
    "ph_value": "6.8",
    "column_name": "No simultaneous infusion/ dedicated lumen",
    "mark_type": "Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "dalbavancin",
    "superscript_number": "1,39,40",
    "ph_value": null,
    "column_name": "Phlebitis.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "delafloxacin meglumine",
    "superscript_number": "1,41",
    "ph_value": "NR*",
    "column_name": "Phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "doripenem",
    "superscript_number": "42,43",
    "ph_value": "4.5-5.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "doxycycline hyclate",
    "superscript_number": "1,44",
    "ph_value": "1.8-3.3",
    "column_name": "Thrombo-phlebitis.Potential for damage from extravasation.Absolute vein patency needed",
    "mark_type": "Circle.Circle.Circle",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "eravacycline",
    "superscript_number": "1,45,46",
    "ph_value": "5.5-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "ertapenem",
    "superscript_number": "1,47",
    "ph_value": "7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 6,
    "row_name": "erythromicin lactobionate",
    "superscript_number": "1,48",
    "ph_value": "6.5-7.7",
    "column_name": "Local site pain on Infusion.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Diamond.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "fosfomycin",
    "superscript_number": "49",
    "ph_value": null,
    "column_name": "Phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "flucloxacillin",
    "superscript_number": "50,51",
    "ph_value": null,
    "column_name": "Phlebitis.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "gentamicin sulfate",
    "superscript_number": "1,52",
    "ph_value": "3.0-5.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "imipenem-cilastatin",
    "superscript_number": "1,53",
    "ph_value": "6.5-8.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "meropenem and\nvaborbactam",
    "superscript_number": "1,54,55",
    "ph_value": null,
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "netilmicin",
    "superscript_number": "55,57",
    "ph_value": "3.5-6.0",
    "column_name": "Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "ofloxacin",
    "superscript_number": "58,59,60",
    "ph_value": "2-9",
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain.Redness at injection site",
    "mark_type": "Circle.Circle.Circle.Circle",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "plazomicin",
    "superscript_number": "61,62",
    "ph_value": "6.5",
    "column_name": "No simultaneous infusion/ dedicated lumen",
    "mark_type": "Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "lefamulin",
    "superscript_number": "1,63",
    "ph_value": "4.5-5.5",
    "column_name": "Phlebitis.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "levofloxacin",
    "superscript_number": "1,64,65",
    "ph_value": "3.8-5.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Thrombosis of vessel.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "lincomycin\nhydrochloride",
    "superscript_number": "1,66",
    "ph_value": "3.0-5.5",
    "column_name": "Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "linezolid",
    "superscript_number": "1,67",
    "ph_value": "4.8",
    "column_name": "No simultaneous infusion/ dedicated lumen",
    "mark_type": "Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "meropenem",
    "superscript_number": "1,68",
    "ph_value": "7.3-8.3",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "metronidazole\nhydrochloride",
    "superscript_number": "1,69,70",
    "ph_value": "4.5-7.0",
    "column_name": "Thrombo-phlebitis.Potential for damage from extravasation.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Diamond.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "minocycline\nhydrochloride",
    "superscript_number": "1,71",
    "ph_value": "4.5-5.0",
    "column_name": "Thrombo-phlebitis.Potential for damage from extravasation.Absolute vein patency needed.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "moxifloxacin hydrochloride",
    "superscript_number": "1,72",
    "ph_value": "4.1-4.6",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 8,
    "row_name": "nafcillin sodium",
    "superscript_number": "1,73",
    "ph_value": "6-8.5",
    "column_name": "Thrombo-phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 9,
    "row_name": "fosfomycin 49",
    "superscript_number": "49",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "superscript_in_statement": "49"
  },
  {
    "page_number": 9,
    "row_name": "flucloxacillin 50,51",
    "superscript_number": "50,51",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration. 50",
    "superscript_in_statement": "50"
  },
  {
    "page_number": 9,
    "row_name": "gentamicin sulfate 1,52",
    "superscript_number": "1,52",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Do not physically premix with other drugs. Inactivated in solution with beta-lactam antibiotics and vancomycin. Appropriate spacing required because of incompatibilities.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "imipenem-cilastatin 1,53",
    "superscript_number": "1,53",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Do not mix with or physically add other antibiotics. May be given through y-tube or three-way stopcock of infusion set. Use small needles and large veins, and rotate infusion sites.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "meropenem and\nvaborbactam 1,54,55",
    "superscript_number": "1,54,55",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Only compatible with NS. A single dose as an infusion equally distributed over 3 hours.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "netilmicin 55,57",
    "superscript_number": "55,57",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Ofloxacin solution for infusion should be administered only by slow IV infusion over a period of 30-60 minutes. Fluoroquinolones, including ofloxacin, are associated with an\nincreased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in\npatients with kidney, heart or lung transplants. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients\nwith known history of myasthenia gravis. 60",
    "superscript_in_statement": "60"
  },
  {
    "page_number": 9,
    "row_name": "ofloxacin 58,59,60",
    "superscript_number": "58,59,60",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Administer ZEMDRI 15 mg/kg every 24 hours by intravenous (IV) infusion over 30 minutes to patients 18 years of age or older with creatinine clearance greater than or equal to 90\nmL/min. ZEMDRI should not be mixed with other drugs or physically added to solutions containing other drugs. Other medications should not be infused simultaneously with\nZEMDRI through the same IV line.62",
    "superscript_in_statement": "62"
  },
  {
    "page_number": 9,
    "row_name": "plazomicin 61,62",
    "superscript_number": "61,62",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "A single dose as an infusion equally distributed over 60 minutes. Do not exceed the recommended rate of administration; may increase the magnitude of QT prolongation. Do not\nadd other additives to the diluent bag because their compatibilities with lefamulin have not been established.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "lefamulin 1,63",
    "superscript_number": "1,63",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Temporarily discontinue other solutions infusing at the same site and flush tubing with compatible solutions before and after levofloxacin.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "levofloxacin 1,64,65",
    "superscript_number": "1,64,65",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Manufacturer lists as incompatible with kanamycin and novobiocin. Manufacturer lists the following compatibilities. Infuse properly diluted solution at a rate not to exceed 100\nmL/hr (1 Gm/hr).¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "lincomycin\nhydrochloride 1,66",
    "superscript_number": "1,66",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Manufacturer lists as incompatible at the Y-site with amphotericin B (conventional), ceftriaxone (Rocephin), chlorpromazine (Thorazine), diazepam (Valium), erythromycin\n(Erythrocin), pentamidine, phenytoin (Dilantin), and sulfamethoxazole/trimethoprim.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "linezolid 1,67",
    "superscript_number": "1,67",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Meropenem should not be mixed or physically added to solutions containing other drugs; compatibility not established.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "meropenem 1,68",
    "superscript_number": "1,68",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Administer separately, discontinue the primary IV during administration and do not introduce additives into the solution.¹ Local reactions include thrombophlebitis after intravenous\ninfusion. This reaction can be minimized or avoided by avoiding prolonged use of indwelling intravenous catheters. 69 Administer by slow intravenous drip infusion only, either as a\ncontinuous or intermittent infusion. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.70",
    "superscript_in_statement": "1,69,70"
  },
  {
    "page_number": 9,
    "row_name": "metronidazole\nhydrochloride 1,69,70",
    "superscript_number": "1,69,70",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Additives or other medications should not be added to the minocycline vial or infused simultaneously through the same IV line, including Y-connectors. If the same IV line is used for\nsequential infusion of additional medications, the line should be flushed before and after infusion of minocycline with NS, dextrose, dextrose in saline solutions, or LR.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "minocycline\nhydrochloride 1,71",
    "superscript_number": "1,71",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Manufacturer states, \"Other IV substances, additives, or other medications should not be added to moxifloxacin or infused simultaneously through the same IV line.\" Flush line with a\nsolution compatible to both drugs before and after administration of moxifloxacin and/or any other drug through the same IV line. May be administered through a Y-tube.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "moxifloxacin\nhydrochloride 1,72",
    "superscript_number": "1,72",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Appropriate spacing and/or separate sites required. May be infused over\n5 to 10 minutes.¹",
    "superscript_in_statement": "1"
  },
  {
    "page_number": 9,
    "row_name": "nafcillin sodium 1,73",
    "superscript_number": "1,73",
    "ph_value": null,
    "column_name": "Additional Consideration",
    "mark_type": null,
    "statement": "IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "superscript_in_statement": "49"
  },
  {
    "page_number": 10,
    "row_name": "omadacycline",
    "superscript_number": "1,74",
    "ph_value": null,
    "column_name": "Phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site",
    "mark_type": "Circle.Circle.Circle.Circle",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "oritavancin",
    "superscript_number": "1,75",
    "ph_value": "3.1-4.3",
    "column_name": "Phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "oxacillin",
    "superscript_number": "1,76,77",
    "ph_value": "6-8.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "penicillin g aqueous",
    "superscript_number": "1,78",
    "ph_value": "5.5-8",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "piperacillin-tazobactam",
    "superscript_number": "1,79,80",
    "ph_value": "5.5-6.8",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "rifampim",
    "superscript_number": "1,81",
    "ph_value": "7.8-8.8",
    "column_name": "Phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "sulfamethoxazole-trimethoprim",
    "superscript_number": "1,82",
    "ph_value": "9.5-10.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "tedizolid",
    "superscript_number": "1,83",
    "ph_value": "7.4-8.1",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "teicoplanin",
    "superscript_number": "84,85",
    "ph_value": "7.2-7.8",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "televancin",
    "superscript_number": "1,86",
    "ph_value": "4.5-5.0",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "ticarcillin & clavulanate",
    "superscript_number": "87,88",
    "ph_value": "5.5-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "tigecycline",
    "superscript_number": "1,89,90",
    "ph_value": "7.8",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "tobramycin",
    "superscript_number": "1,91,92",
    "ph_value": "3.0-6.5",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 10,
    "row_name": "vancomycin",
    "superscript_number": "1,93,94,95",
    "ph_value": "2.5-5.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Thrombosis of vessel.Local site pain on Infusion.Absolute vein patency needed.Rotation of peripheral infusion sites recommended.No simultaneous infusion/ dedicated lumen",
    "mark_type": "Circle.Diamond.Circle.Circle.Circle.Circle.Diamond",
    "statement": null,
    "superscript_in_statement": null
  },
  {
    "page_number": 12,
    "row_name": "Reference",
    "superscript_number": null,
    "ph_value": null,
    "column_name": null,
    "mark_type": null,
    "statement": null,
    "superscript_in_statement": null
  }
]